| Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy | 09/06 09:20 | businesswire.com |
| CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030 | 08/30 04:04 | globenewswire.com |
| Ligand Pharmaceuticals Incorporated (LGND) Q2 2024 Earnings Call Transcript | 08/06 22:58 | seekingalpha.com |
| Ligand Pharmaceuticals: Solid Performer Performing Solidly | 07/29 14:43 | seekingalpha.com |
| Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 | 07/23 16:01 | businesswire.com |
| 5 Best Short-Term Stocks to Consider Investing In | 07/10 09:01 | marketbeat.com |
| Ligand to Acquire APEIRON Biologics AG for $100 Million | 07/08 07:00 | businesswire.com |
| Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years | 06/27 08:00 | businesswire.com |
| Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults | 06/18 08:00 | businesswire.com |
| What Makes Ligand (LGND) a New Strong Buy Stock | 06/14 13:01 | zacks.com |